August 13, 2025Open Access

A novel composite index of PSA and periprostatic adipose tissue quantification for enhancing high-grade prostate cancer prediction

Key Points

Incorporating the PSA and PPFA/PA index significantly improves high-grade prostate cancer prediction, enhancing clinical decision-making.
Key metrics include PSA and periprostatic fat area ratios, with odds ratios significant at P ≤ 0.022, highlighting their predictive value.
Assessment utilized multivariate binary logistic regression, ROC curves, and AUC calculations for model performance evaluation.
The study suggests that integrating quantitative PPAT data provides a more effective tool in identifying high-grade prostate cancer risk.

Abstract

To explore the efficacy of combining MRI-derived quantitative data on Periprostatic adipose tissue (PPAT) with clinical biomarkers, including prostate-specific antigen (PSA), to enhance the high-grade (PCa) screening. In a retrospective analysis, we reviewed clinical and pathological records of patients who had undergone prostate MRI between January 2020 and January 2023. Two radiologists measured PPAT metrics - subcutaneous fat thickness (SFT), periprostatic fat thickness (PPFT), periprostatic fat area (PPFA), and periprostatic fat volume (PPFV) - on T1-weighted axial images. Ratios of PPFA to prostate area (PA) (PPFA/PA) and PPFV to prostate volume (PV) (PPFV/PV) were calculated, collinearity testing was performed, and differences between groups for PPAT metrics and PSA levels were analyzed. Selected variables underwent multivariate binary logistic regression to identify independent predictors of high-grade PCa. Model performance was assessed using ROC curves and AUC. The study included 215 patients. Significant differences between high- and low-grade PCa groups were observed for PPFA, PPFA/PA, PSA, Prostate specific antigen density (PSAD) and the combined index PSA×PPFA/PA (P ≤ 0.001). Multivariate analysis identified PPFA/PA and PSA levels as independent predictors of high-grade PCa, with odds ratios (OR) of 1.011 (95% CI 1.002-1.021, P = 0.018) and 1.044 (95% CI 1.006-1.082, P = 0.022), respectively. The PSA, PSAD, PSA × PPFA/PA, and composite indicator models demonstrated strong predictive performance, with AUC values of 0.771, 0.796, 0.818, and 0.814, respectively. Among these, the PSA × PPFA/PA model showed superior performance, with an optimal cutoff value of 42.135. The PSA×PPFA/PA index promises enhanced prediction of high-grade PCa, demonstrating that incorporating PPAT measurements alongside PSA improves screening efficacy and supports more informed clinical decision-making in the management of PCa. Not applicable.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper